Vemurafenib Limits Influenza A Virus Propagation by Targeting Multiple Signaling Pathways

Area of Science:

• Virology
• Molecular Biology
• Pharmacology

Background:

• Influenza A virus (IAV) poses a pandemic threat, necessitating novel antiviral strategies due to existing drug limitations and resistance.
• The cellular Raf/MEK/ERK signaling pathway is vital for IAV replication and represents a potential antiviral target.
• Clinically approved Raf and MEK inhibitors are available, stemming from their role in cancer therapy.

Purpose of the Study:

• To investigate the antiviral potential of Vemurafenib, a B-Raf inhibitor, against Influenza A virus (IAV).
• To elucidate the mechanism of action of Vemurafenib in the context of IAV infection and its impact on cellular signaling pathways.

Main Methods:

• Treatment of cells with Vemurafenib during IAV infection.
• Analysis of Raf/MEK/ERK signaling cascade activation.
• Assessment of p38 and JNK mitogen-activated protein kinase (MAPK) pathway activity.
• Evaluation of virus-induced apoptosis and viral protein expression.

Main Results:

• Vemurafenib treatment led to hyperactivation of the Raf/MEK/ERK cascade but inhibited IAV-induced activation of p38 and JNK MAPK pathways.
• The drug suppressed virus-induced apoptosis by reducing apoptosis-inducing cytokine expression.
• Vemurafenib significantly hampered viral protein expression, correlating with decreased p38 and JNK MAPK activation.
• A profound inhibition of viral replication was observed, with viral titers reduced by up to three orders of magnitude.

Conclusions:

• Vemurafenib exhibits potent antiviral activity against IAV through a multi-target mechanism distinct from direct Raf/MEK/ERK inhibition.
• The drug's ability to inhibit apoptosis and viral protein synthesis contributes to its broad antiviral efficacy.
• Vemurafenib represents a promising candidate for developing novel influenza therapeutics.